ABSTRACT
Objective:To analyze the clinical effect of real-time virtual sonography (RVS) surgical navigation combined with indocyanine green fluorescence imaging technology in the anatomical liver segmentectomy for hepatocellular carcinoma (HCC).Methods:The clinical data of 35 patients who underwent anatomical liver segmentectomy using RVS surgical navigation combined with indocyanine green fluorescence imaging technology in the Department of Hepatobiliary Surgery of Peking University International Hospital from January 2020 to January 2022 were retrospectively analyzed. There were 22 males and 13 females, aged (60.0±10.0) years. RVS is real-time virtual sonography, which fuses real-time intraoperative ultrasound images with corresponding preoperative CT or MRI images to guide the surgical plane. Methods of operation, time of operation, intraoperative blood loss, operative margin, hospital stay and postoperative complications were analyzed. Postoperative complications were graded by Clavien-Dindo system. The 1-year overall survival and tumor-free survival rates of patients were followed up by outpatient or telephone review.Results:Anatomical liver segmentectomy was performed on 36 patients, including 1 patient (2.9%) of segment Ⅱ, 1 patient (2.9%) of segment Ⅲ, 5 patients (14.3%) of segment Ⅳ, 6 patients (17.1%) of segment Ⅴ, 10 patients (28.6%) of segment Ⅵ, 7 patients (20.0%) of segment Ⅶ, 4 patients (11.4%) of segment Ⅷ, and 1 patient (2.9%) of segments Ⅴ+ Ⅷ. The operation time of 35 patients was (310.2±81.6) min, with an intraoperative blood loss of [ M( Q1, Q3)] 390.0(250.0, 500.0) ml. The hospital stay was (11.6±2.1) d. There was no postoperative death. Postoperative complications occurred in 3 cases (8.6%), of which 2 cases (5.7%) were ascites, Clavien-Dindo grade Ⅰ; Postoperative hemorrhage occurred in 1 case (2.9%), Clavien-Dindo grade Ⅱ. HCC was confirmed by pathology in all cases, and the operative margins were negative. The median follow-up time was 14 months (12 to 20 months). The 1-year overall survival rate after surgery was 100.0%(35/35), three patients (8.6%) had tumor recurrence, and the 1-year tumor-free survival rate was 91.4% (32/35). Conclusion:RVS surgical navigation combined with indocyanine green fluorescence imaging technology could be feasible in anatomical segmental hepatectomy for HCC.
ABSTRACT
Gastric schwannoma is a tumor originating from mesenchymal tissue. The clinical incidence is relatively rare, accounting for 6.3% of all gastric stromal tumors. The tumor is more likely to occur in the body of the stomach and usually originates from the gastric submucosal nerve. Most gastric schwannomas do not have any clinical symptoms. Imaging examination can play a diagnostic role, but the diagnosis still requires pathological examination, especially S-100 protein which is the gold standard for the diagnosis of gastric schwannomas. Gastric schwannoma usually needs to be distinguished from gastrointestinal stromal tumors and gastrointestinal autonomic nerve tumors. In terms of treatment, complete surgical resection is the first choice.
ABSTRACT
Adenocarcinoma of esophagogastric junction is located in the special anatomical location,which is different from esophageal cancer and gastric cancer in biological characteristics.Therefore,the definition,clinical classification and tumor staging are controversial.Currently the classification of Siewert is accepted by worldwide.Meanwhile,there is a relatively independent TNM staging based on the tumor site,this TNM stage can guide subsequent treatment accurately and judge prognosis.Thus,clinicians need to further study about the definition of adenocarcinama of esophagogastric junction and esophagogastric junction,clinical classification and tumor stage.In addition,we expect to perform basic and clinical research in future to get more high level evidence in order to provide treatment accurately for patients.
ABSTRACT
Adenocarcinoma of the esophagogastric junction is a special type of tumor,not only in the special location,but also in the biological characteristics and clinical manifestations are unique.Surgery is the main treatment,but surgery alone sometimes result in poor prognosis,as a new direction of cancer treatment,Molecular targeting therapy is playing an increasingly important role.Some molecular targets such as vascular endothelial growth factor,hepatocyte growth factor receptor,epidermal growth factor receptor,fibroblast growth factor receptor 2,human epidermal growth factor receptor-2 in the treatment of esophageal gastric adenocarcinoma show a broad prospect.This review summarizes the current status and progress of molecular targeted therapy of adenocarcinoma of esophagogastric junction.